BNP Paribas Financial Markets Buys 113,797 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

BNP Paribas Financial Markets boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 394.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,628 shares of the biopharmaceutical company's stock after acquiring an additional 113,797 shares during the quarter. BNP Paribas Financial Markets owned about 0.15% of Ultragenyx Pharmaceutical worth $6,000,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of RARE. Vanguard Group Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock worth $422,167,000 after purchasing an additional 89,389 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Ultragenyx Pharmaceutical by 1.5% in the fourth quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock valued at $71,509,000 after buying an additional 25,487 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Ultragenyx Pharmaceutical by 5.3% during the 4th quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock valued at $68,487,000 after acquiring an additional 81,667 shares during the last quarter. Alyeska Investment Group L.P. grew its holdings in shares of Ultragenyx Pharmaceutical by 23.1% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock worth $60,570,000 after acquiring an additional 269,733 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its position in shares of Ultragenyx Pharmaceutical by 125.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock worth $49,375,000 after purchasing an additional 653,088 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CAO Theodore Alan Huizenga sold 967 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the transaction, the chief accounting officer now owns 50,265 shares of the company's stock, valued at $2,116,156.50. This trade represents a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Howard Horn sold 1,785 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the sale, the chief financial officer now directly owns 106,169 shares of the company's stock, valued at approximately $4,289,227.60. This represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 125,405 shares of company stock worth $5,285,169. Corporate insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock traded up $0.77 during trading on Friday, hitting $35.61. 616,642 shares of the stock traded hands, compared to its average volume of 827,582. The stock has a market cap of $3.37 billion, a P/E ratio of -5.62 and a beta of 0.34. The company has a fifty day moving average price of $36.45 and a two-hundred day moving average price of $41.89. Ultragenyx Pharmaceutical Inc. has a twelve month low of $29.59 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. During the same quarter last year, the firm earned ($2.03) earnings per share. Ultragenyx Pharmaceutical's revenue was up 28.0% compared to the same quarter last year. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on RARE. Canaccord Genuity Group lifted their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. HC Wainwright reissued a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Morgan Stanley upped their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. JPMorgan Chase & Co. raised their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and an average target price of $90.93.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.